Ensign Peak Advisors
TARS icon

Ensign Peak Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Ensign Peak Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.9M Sell
268,696
-64,286
-19% -$4.11M 0.03% 350
2026
Q1 		$23.4M Sell
332,982
-141,068
-30% -$9.86M 0.04% 281
2025
Q4 		$38.8M Sell
474,050
-8,314
-2% -$621K 0.07% 211
2025
Q3 		$28.7M Sell
482,364
-4,946
-1% -$244K 0.05% 262
2025
Q2 		$19.7M Hold
487,310
– – 0.03% 321
2025
Q1 		$25M Sell
487,310
-82,746
-15% -$4.09M 0.05% 268
2024
Q4 		$31.6M Sell
570,056
-16,974
-3% -$771K 0.06% 246
2024
Q3 		$19.3M Sell
587,030
-7,295
-1% -$205K 0.03% 335
2024
Q2 		$16.2M Sell
594,325
-133,566
-18% -$4.49M 0.03% 349
2024
Q1 		$26.5M Buy
727,891
+290,000
+66% +$8.53M 0.05% 272
2023
Q4 		$8.87M Hold
437,891
– – 0.02% 467
2023
Q3 		$7.78M Buy
437,891
+195,440
+81% +$3.46M 0.02% 455
2023
Q2 		$4.38M Hold
242,451
– – 0.01% 623
2023
Q1 		$3.05M Hold
242,451
– – 0.01% 694
2022
Q4 		$3.55M Hold
242,451
– – 0.01% 648
2022
Q3 		$4.15M Hold
242,451
– – 0.01% 566
2022
Q2 		$3.54M Hold
242,451
– – 0.01% 620
2022
Q1 		$4.08M Hold
242,451
– – 0.01% 652
2021
Q4 		$5.46M Buy
242,451
+42,451
+21% +$1.1M 0.01% 641
2021
Q3 		$4.31M Hold
200,000
– – 0.01% 721
2021
Q2 		$5.8M Hold
200,000
– – 0.01% 600
2021
Q1 		$6.45M Hold
200,000
– – 0.01% 539
2020
Q4 		$8.27M Buy
+200,000
New +$5.7M 0.02% 469

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ensign Peak Advisors's TARS Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Tarsus Pharmaceuticals (TARS) stake by 19% in Q2 2026, selling an estimated $4.11M and leaving 268,696 shares worth $16.9M. The position accounts for 0.03% of the portfolio, ranked #350.

Ensign Peak Advisors first reported a position in TARS in Q4 2020 and has held it in 23 quarters since. The position peaked at $38.8M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Ensign Peak Advisors held 268,696 shares of Tarsus Pharmaceuticals worth $16.9M as of Q2 2026.
  • Ensign Peak Advisors sold 64,286 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $4.11M.
  • Tarsus Pharmaceuticals made up 0.03% of Ensign Peak Advisors's portfolio in Q2 2026, its #350 holding.
  • Ensign Peak Advisors first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Ensign Peak Advisors's Tarsus Pharmaceuticals position peaked at $38.8M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.